Cargando…

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results

SIMPLE SUMMARY: Survival outcomes with standard cytotoxic chemotherapy are poor, and most patients with ovarian cancer will die with platinum-resistant disease. This may reflect the existence of drug-resistant ovarian cancer stem cells. Cantrixil is a novel third-generation benzopyran molecule, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coward, Jermaine I., Barve, Minal A., Kichenadasse, Ganessan, Moore, Kathleen N., Harnett, Paul R., Berg, Daniel, Garner, James S., Dizon, Don S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268018/ https://www.ncbi.nlm.nih.gov/pubmed/34206826 http://dx.doi.org/10.3390/cancers13133196

Ejemplares similares

Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)
por: Saif, Muhammad Wasif, et al.
Publicado: (2016)

Strangulation of intraperitoneal kidney transplant by fallopian tube
por: Nawabi, Atta, et al.
Publicado: (2021)

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

AB002. Biomarkers for prostate cancer
por: Shindel, Alan
Publicado: (2016)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer
por: Coward, Jermaine, et al.
Publicado: (2014)

New perspectives on targeted therapy in ovarian cancer
por: Coward, Jermaine IG, et al.
Publicado: (2015)

Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers
por: Mercier, Ann Marie, et al.
Publicado: (2023)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
por: van Leuven, Jason, et al.
Publicado: (2023)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies
por: Li, Jordan Y., et al.
Publicado: (2022)

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma
por: Lander, Megan, et al.
Publicado: (2020)

Radiation Induced Leiomyosarcoma Three Decades After Treatment for Wilms’ Tumor
por: Khattak, Muhammad A, et al.
Publicado: (2010)

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report
por: Abbas, M. Nazim, et al.
Publicado: (2021)

Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
por: Obermair, Andreas, et al.
Publicado: (2021)

Targeted pharmacotherapy after somatic cancer mutation screening
por: Polasek, Thomas M., et al.
Publicado: (2016)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
por: Acs, Miklos, et al.
Publicado: (2022)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer
por: Sakamoto, Shuichi, et al.
Publicado: (2019)

Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
por: Malczewski, Agnieszka Beata, et al.
Publicado: (2020)

Evaluation of selective bone scan staging in prostate cancer – external validation of current strategies and decision-curve analysis
por: Hiwase, Mrunal D., et al.
Publicado: (2022)

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
por: Tokunaga, Hideki, et al.
Publicado: (2021)

Outcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
por: Hamontri, Suttha, et al.
Publicado: (2023)

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
por: Berek, Jonathan S., et al.
Publicado: (2021)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity
por: Lei, Hong, et al.
Publicado: (2018)

Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer
por: Qu, Tao, et al.
Publicado: (2019)

Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
por: Lim, Myong Cheol, et al.
Publicado: (2018)

Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
por: Farrell, Rhonda, et al.
Publicado: (2021)

A Retrospective Cross-Sectional Cohort Trial Assessing the Prevalence of MTHFR Polymorphisms and the Influence of Diet on Platinum Resistance in Ovarian Cancer Patients
por: Phillips-Chavez, Caitlin, et al.
Publicado: (2021)

TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport
por: Zhang, Yushuo, et al.
Publicado: (2017)

Breast cancer and sexual function
por: Boswell, Erica N., et al.
Publicado: (2015)

Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review
por: van Dyk, Madelé, et al.
Publicado: (2021)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites
por: Malczewski, Agnieszka Beata, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m6cql2l29d6u7fdlhn0mn9tca8